4D Molecular Therapeutics (FDMT) EBT Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 88.57% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 213.87% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 76.48% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -12.04% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 530.43% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 96.45% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -14.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.64% |
| Mar 31, 2026 | -91.98% |
| Dec 31, 2025 | 135.65% |
| Sep 30, 2025 | -10.16% |
| Jun 30, 2025 | -97.77% |
| Mar 31, 2025 | -26.57% |
| Dec 31, 2024 | -52.85% |
| Sep 30, 2024 | -168.03% |
| Jun 30, 2024 | 11.36% |
| Mar 31, 2024 | 20.76% |
| Dec 31, 2023 | -9.21% |
| Sep 30, 2023 | 38.54% |
| Jun 30, 2023 | -49.81% |
| Mar 31, 2023 | -48.79% |
| Dec 31, 2022 | -15.25% |
| Sep 30, 2022 | 0.45% |
| Jun 30, 2022 | -217.09% |
| Mar 31, 2022 | 22.89% |
| Dec 31, 2021 | 77.64% |
| Sep 30, 2021 | -508.45% |